Key takeaways
View moreDespite the recent stock price decline, UnitedHealth Group's EV/Sales ratio of 1.4x remains significantly above the industry average of 0.79x, suggesting overvaluation even after accounting for superior profitability metrics. The company faces substantial near-term headwinds including rising medical costs, regulatory pressures, and liquidity concerns, while the potential catalysts for value creation appear more long-term in nature and subject to execution risk.
- UnitedHealth Group's revenue is growing, with sales reaching $109.58 billion in Q1 2025, but profitability is under pressure due to rising medical costs, particularly in the Medicare Advantage segment, as highlighted in the earnings call.
- The company's liquidity position is concerning, with a current ratio of 0.85 in Q1 2025, below the industry average of 1.28, indicating potential short-term financial challenges.
- UNH's stock price has declined significantly, dropping approximately 49% from April 10, 2025, to June 6, 2025, reflecting negative market sentiment following a revised earnings outlook.
- The Enterprise Value to Sales ratio of 1.4 is higher than the industry average of 0.79, suggesting that the company may be overvalued relative to its sales.
- Management has revised the adjusted earnings per share outlook for 2025 to $26-$26.50 due to increased care activity in UnitedHealthcare's Medicare Advantage business and unanticipated changes in Optum Medicare membership, as stated in the earnings call.
- Compared to the Health Care Select Sector SPDR Fund (XLV), UNH has significantly underperformed, with a YTD return of -38.02% compared to XLV's -3.8%, indicating substantial underperformance.
- The company faces key risks related to managing medical costs, regulatory pressures, and cybersecurity threats, as detailed in the SEC filings.
- UNH is focused on expanding its Optum business and growing its Medicare Advantage membership, aiming to add 800,000 new members, as mentioned in the earnings call.
- The total debt to total equity ratio was 85.51% in Q1 2025, close to the industry average of 83.72%, indicating moderate financial leverage.
- The company's ability to successfully implement corrective actions and return to its long-term earnings per share growth target of 13% to 16% will be crucial for its future performance, as emphasized by management.
Evaluation summary
Add to research
-
Company Overview:
- UnitedHealth Group, Inc. (UNH) is a diversified health care and well-being company. It operates through two main segments: Optum and UnitedHealthcare. Optum provides health services including care delivery, data analytics, and pharmacy care, while UnitedHealthcare offers health benefit plans for various groups, including employers, individuals, and Medicare/Medicaid beneficiaries.
- Key products and services include risk-based health plans, value-based care arrangements, pharmacy benefits management, and health care technology and consulting. The company's revenue is generated from premiums, fees, and sales of products and services. While specific revenue breakdowns by product are not provided, the SEC filings indicate that Optum Rx, UnitedHealthcare's domestic offerings, and Optum Health are significant revenue drivers.
- The benchmarks used for comparative analysis include the Health Care Select Sector SPDR Fund (XLV), and the peer companies used for comparison are Humana, Inc. (HUM) and Elevance Health, Inc. (ELV).
-
Financial Performance:
- UnitedHealth Group's revenue has shown a strong increasing trend. The sales/revenue increased from $98.86 billion in Q2 2024 to $109.58 billion in Q1 2025.
- Net income has fluctuated, with a high of $6.29 billion in Q1 2025 and a low of $4.22 billion in Q2 2024. The net profit margin was 5.74% in Q1 2025, 5.5% in Q4 2024, 6.01% in Q3 2024, and 4.26% in Q2 2024.
- Return on Average Assets (ROA) was 7.44% in Q1 2025, 4.96% in Q4 2024, 4.93% in Q3 2024, and 4.98% in Q2 2024. Return on Average Total Equity (ROE) was 24.33% in Q1 2025, 15.88% in Q4 2024, 15.99% in Q3 2024, and 16.43% in Q2 2024. Return on Average Total Capital was 18.06% in Q1 2025, 13.67% in Q4 2024, 14.05% in Q3 2024, and 14.28% in Q2 2024.
- Compared to the industry average, UNH's ROA, ROE, and Return on Average Total Capital are significantly higher, indicating superior profitability. The industry average ROA is -1.67%, ROE is -35.69%, and Return on Average Total Capital is 1.16%. UNH's Net Profit Margin of 5.74% in Q1 2025 is also significantly higher than the industry average of -0.97%.
- The recent earnings call highlighted a revised adjusted earnings per share outlook for 2025 due to increased care activity in UnitedHealthcare's Medicare Advantage business and unanticipated changes in Optum Medicare membership, impacting financial performance negatively.
-
Operational Efficiency:
- Total assets have increased from $286.06 billion in Q2 2024 to $309.79 billion in Q1 2025. Total liabilities have also increased from $186.82 billion in Q2 2024 to $204.62 billion in Q1 2025.
- Working capital, calculated as current assets minus current liabilities, can be estimated using the provided data. However, a precise calculation is not possible without a detailed breakdown of current assets and liabilities.
- Net operating cash flow has fluctuated, with a high of $13.95 billion in Q3 2024 and a low of $2.37 billion in Q4 2024. In Q1 2025, net operating cash flow was $5.46 billion. Total capital expenditure was $898 million in Q1 2025.
- Free cash flow to equity was $4.56 billion in Q1 2025. Free cash flow margins can be estimated by dividing free cash flow by sales/revenue.
- Capital expenditure was $898 million in Q1 2025, $912 million in Q4 2024, $991 million in Q3 2024, and $853 million in Q2 2024. Accumulated depreciation data is not provided.
- Cash dividends paid were approximately $1.9 billion per quarter. Change in capital stock was -$2.64 billion in Q1 2025 and -$4.74 billion in Q4 2024, indicating share repurchases.
- The current ratio was 0.85 in Q1 2025, 0.83 in Q4 2024, 0.91 in Q3 2024, and 0.88 in Q2 2024, which is below the industry average of 1.28, suggesting potential liquidity issues.
- The total debt to total equity ratio was 85.51% in Q1 2025, 88.27% in Q4 2024, 82.52% in Q3 2024, and 84.04% in Q2 2024, which is close to the industry average of 83.72%, indicating moderate financial leverage.
-
Growth Opportunities:
- The company is focused on expanding its Optum business, including care delivery, data/analytics, and pharmacy services, as highlighted in the SEC filings.
- The earnings call mentioned that UnitedHealthcare's Medicare Advantage business is on pace to serve an additional 800,000 people, and Optum Health is on track to add 650,000 net new patients to value-based care arrangements.
- Optum Rx is experiencing strong growth, driven by new wins and high retention of long-term customers.
- The company is investing in digital engagement tools, which have sparked a more than 40% increase in digital engagement among senior members.
- Capital allocation strategies include investments in strategic initiatives, dividends, and share repurchases.
-
Recent Developments and Market Sentiment:
- Recent news indicates a significant drop in UNH's stock price following a revised earnings outlook for 2025. This revision was attributed to increased care activity in UnitedHealthcare's Medicare Advantage business and unanticipated changes in Optum Medicare membership.
- The market sentiment appears negative, as reflected in the sharp stock price decline. Investors are concerned about the company's ability to manage medical costs and maintain profitability in the face of rising utilization and regulatory pressures.
- The earnings call highlighted management's commitment to addressing these challenges through corrective actions and strategic initiatives. However, the near-term outlook remains uncertain, and the company's ability to return to its long-term growth targets is being questioned by analysts.
- These developments align with the company's strategic objectives of growth and innovation but diverge from its financial performance targets, necessitating immediate and effective management actions.
-
Risks and Threats:
- Key risks identified in the SEC filings include the ability to effectively estimate, price, and manage medical costs, potential failures or disruptions to information systems, and regulatory changes.
- The earnings call highlighted the Medicare Advantage utilization spike and patient profile shift in Optum Health as significant challenges to profitability.
- Competitive threats include a range of organizations, including startups, large enterprises, non-profits, and government entities.
- Regulatory risks include government investigations, audits, and legal proceedings related to business practices and compliance matters.
- The Change Healthcare cyberattack in 2024 caused significant business disruption and incurred substantial costs, highlighting the vulnerability to cybersecurity incidents.
-
Valuation Analysis:
- The Enterprise Value to Sales ratio is 1.4, which is higher than the industry average of 0.79, suggesting that the company may be overvalued relative to its sales.
- The industry average Enterprise Value to EBITDA is 10.45, but UNH's specific EV/EBITDA is not provided.
- Potential catalysts include successful implementation of corrective actions to address performance challenges and return to long-term growth targets. Headwinds include rising medical costs, regulatory pressures, and cybersecurity risks.
-
Price Performance:
- The stock price has experienced a significant decline in recent months. The price dropped from $594.40 on April 10, 2025, to $303.22 on June 6, 2025, representing a decrease of approximately 49%.
- Compared to the Health Care Select Sector SPDR Fund (XLV), UNH has significantly underperformed. The Year-To-Date (YTD) return for UNH is -38.02%, while XLV has a return of -3.8%.
- Compared to peers Humana (HUM) and Elevance Health (ELV), UNH has also underperformed in recent periods.
-
Future Outlook:
- Management has revised the adjusted earnings per share outlook for 2025 to $26-$26.50 due to increased care activity in UnitedHealthcare's Medicare Advantage business and unanticipated changes in Optum Medicare membership.
- The company aims to return to its long-term earnings per share growth target of 13% to 16%.
- Recent news and developments are expected to negatively influence the company's near-term performance, but management is focused on corrective actions to improve performance in the rest of 2025 and into 2026.
-
Summary:
- UnitedHealth Group is a diversified health care leader with strong revenue growth but faces challenges related to medical cost management, regulatory pressures, and cybersecurity risks.
- The company's liquidity position needs to be monitored closely, as the current ratio is below the industry average.
- The increasing debt levels raise concerns about long-term solvency, requiring careful management of debt obligations.
- The Medicare Advantage utilization spike and patient profile shift in Optum Health pose significant challenges to profitability and require immediate and effective management.
- The company's ability to generate consistent cash flow is crucial for sustaining its growth and shareholder returns.
- SWOT Analysis:
- Strengths: Diversified business model, strong revenue growth, and market position.
- Weaknesses: Rising medical costs, liquidity concerns, and increasing debt levels.
- Opportunities: Expansion of Optum business, growth in Medicare Advantage, and digital engagement initiatives.
- Threats: Regulatory pressures, cybersecurity risks, and competitive landscape.
- Overall financial health assessment indicates moderate financial stability, but the company needs to address the challenges related to medical cost management and regulatory pressures to sustain its growth trajectory.
- Critical factors for future performance include effective management of medical costs, successful implementation of corrective actions, and adaptation to regulatory changes.
- Areas requiring further monitoring include liquidity position, debt levels, and the impact of regulatory changes on profitability.
- Investment profile assessment: UNH faces significant headwinds, reflected in its recent stock price decline. While the company has strong fundamentals and growth opportunities, the near-term outlook is uncertain due to rising medical costs and regulatory pressures. The company's ability to successfully implement corrective actions and return to its long-term growth targets will be crucial for its future performance.
Price history
Add to research
Fundamentals
Add to research
Insights
- UnitedHealth Group demonstrates strong revenue growth and profitability, but faces challenges related to medical cost management, regulatory pressures, and cybersecurity risks.
- The company's liquidity position needs to be monitored closely, as the current ratio is below 1 and lower than the industry average.
- The increasing debt levels raise concerns about long-term solvency, requiring careful management of debt obligations.
- The Medicare Advantage utilization spike and patient profile shift in Optum Health pose significant challenges to profitability and require immediate and effective management.
- The company's ability to generate consistent cash flow is crucial for sustaining its growth and shareholder returns.
Analysis
- Revenue
- Revenue has shown a strong increasing trend, indicating robust growth in the company's core business operations.
- The growth in sales/revenue is decelerating, suggesting a need for continued innovation and market expansion to sustain high growth rates.
- The Enterprise Value to Sales ratio is higher than the industry average, indicating that the company may be overvalued relative to its sales.
- Profitability
- Profitability metrics, such as Return on Average Assets, Return on Average Total Equity, and Return on Average Total Capital, are strong and increasing, demonstrating the company's ability to generate profit.
- The Net Profit Margin is significantly higher than the industry average, indicating superior profitability.
- The Medicare Advantage utilization spike and patient profile shift in Optum Health, as noted in the earnings call, could pose challenges to profitability if not managed effectively.
- Liquidity
- The Current Ratio is below 1 and lower than the industry average, suggesting potential liquidity issues.
- The company needs to monitor its short-term obligations and ensure sufficient liquid assets to meet its liabilities.
- The SEC filings highlight the risk of potential failures or disruptions to information systems and technology, including cybersecurity incidents, which could impact liquidity.
- Solvency
- The Total Debt to Total Equity Ratio is increasing, indicating higher financial leverage.
- The company needs to manage its debt obligations carefully to maintain long-term solvency.
- The SEC filings mention exposure to government investigations, audits, and legal proceedings, which could impact solvency.
- Operational Efficiency
- The company demonstrates efficient revenue generation, as indicated by the growth in premium receivables.
- However, rising operating expenses suggest a need for better cost control measures to improve operational efficiency.
- The earnings call emphasizes the need for cost management and efficiency improvements to mitigate external pressures and return to long-term growth targets.
- Cash Flow Analysis - Cash flows from operations have fluctuated, with a recent increase, driven by net income and adjustments for non-cash items. - Free cash flow is expected to support debt repayment, dividend growth, and investment in organic growth opportunities. - The company's ability to generate consistent cash flow is crucial for sustaining its growth and shareholder returns.
- Risk Factors
- The company faces ongoing challenges around medical cost management, regulatory pressures (especially in Medicare Advantage and Medicaid), and technology/cybersecurity risks that could materially impact its financial performance and operations.
- The Medicare Advantage utilization spike and patient profile shift in Optum Health, as noted in the earnings call, pose significant challenges to profitability.
- The SEC filings highlight the risk of potential failures or disruptions to information systems and technology, including cybersecurity incidents, which could impact liquidity and operations.
- Future Outlook
- The company is projected to show continued revenue growth and profitability, driven by strategic initiatives and market expansion.
- However, the company needs to address the challenges related to medical cost management, regulatory pressures, and cybersecurity risks to sustain its growth trajectory.
- The earnings call emphasizes the need for corrective actions to address performance challenges and return to long-term earnings per share growth targets.
- Profitability
Financial statements
Add to research
Loading...
Public filings
Add to research
- UnitedHealth Group is a diversified health care leader with a strong market position across its Optum and UnitedHealthcare businesses, serving a wide range of customers including employers, health plans, government programs, and care providers.
- The company faces ongoing challenges around medical cost management, regulatory pressures (especially in Medicare Advantage and Medicaid), and technology/cybersecurity risks that could materially impact its financial performance and operations.
- UnitedHealth Group has demonstrated resilience in navigating industry disruptions, such as the Change Healthcare cyberattack, and continues to invest in growth initiatives, particularly within its Optum segment.
- The company's financial position remains strong, with robust cash flow generation and a disciplined approach to capital allocation, including dividends and share repurchases.
- Key risks to monitor include the company's ability to effectively price and manage medical costs, maintain critical stakeholder relationships, adapt to regulatory changes, and protect its technology infrastructure from cyber threats.
Core Business and Operations:
- UnitedHealth Group is a diversified health care and well-being company with two main business segments:
- Optum - Provides a range of health services including care delivery, population health management, data analytics, pharmacy care services, and technology solutions
- UnitedHealthcare - Offers a full suite of health benefit plans and services for employers, individuals, Medicare and Medicaid beneficiaries
- Key products and services include risk-based health plans, value-based care arrangements, pharmacy benefits management, data analytics, and health care technology and consulting
- Major customers include employers, health plans, government programs (Medicare, Medicaid), care providers, and life sciences companies
- Faces competition from a range of organizations including startups, large enterprises, non-profits, and government entities
Industry and Market Trends:
- Overall health care spending in the U.S. continues to grow due to factors like inflation, medical technology advancements, regulatory changes, and demographic trends
- Pricing and medical cost trends remain challenging, especially in the Medicare Advantage and Medicaid markets due to funding pressures and regulatory changes
- Industry is shifting towards value-based care models that aim to improve quality, affordability, and patient experience
- Regulatory environment is complex with various federal and state laws/requirements governing the health care sector
Recent Events:
- Completed the sale of its Brazil operations and initiated the sale of its remaining South American operations
- Experienced significant business disruption and incurred substantial costs due to the 2024 Change Healthcare cyberattack
- Continued to invest in and expand its Optum business, including care delivery, data/analytics, and pharmacy services
Risk Factors:
- Ability to effectively estimate, price, and manage medical costs for risk-based products and services
- Potential failures or disruptions to information systems and technology, including cybersecurity incidents
- Inability to maintain satisfactory relationships with health care providers, payers, and other key stakeholders
- Exposure to government investigations, audits, and legal proceedings
- Regulatory changes and uncertainties, especially around Medicare Advantage and Medicaid programs
- Macroeconomic conditions and their impact on demand for products/services and funding for government programs
Legal Matters:
- Involved in various governmental investigations, audits, and legal proceedings related to business practices, coverage determinations, and compliance matters
- Ongoing DOJ lawsuit alleging improper risk adjustment submissions, with the court recently recommending summary judgment in the company's favor
Management's Discussion and Analysis:
- Consolidated revenues grew 8% in 2024, driven by Optum Rx, UnitedHealthcare's domestic offerings, and Optum Health
- Earnings from operations were relatively flat year-over-year, impacted by the Change Healthcare cyberattack and other factors
- Medical cost trends increased due to elevated utilization, coding intensity, and specialty drug costs, partially offset by cost management efforts
- Strong cash flow generation, with $24.2 billion in operating cash flow for 2024
- Continued to return capital to shareholders through dividends and share repurchases
Earnings calls
Add to research
Earnings Report 2025Q1 (2025-04-17)
Key takeaways
- Medicare Advantage Utilization Spike is a Key Concern: The unexpected surge in care activity within the Medicare Advantage segment, particularly physician and outpatient services, poses a significant challenge to profitability and requires immediate and effective management.
- Optum Health's Patient Profile Shift Requires Adjustment: The influx of new patients into Optum Health with lower engagement levels and higher acuity necessitates operational adjustments and enhanced engagement strategies to improve reimbursement and manage costs effectively.
- Value-Based Care Model Remains a Core Strategy: Despite current headwinds, the company remains committed to its value-based care model, viewing it as a long-term solution for improving healthcare outcomes and controlling costs, but needs to adapt to pricing pressures.
- External Factors Significantly Impact Performance: Medicare funding cuts, CMS risk model changes, and potential pharmaceutical tariffs are creating significant external pressures that require proactive management and strategic adaptation.
- Cost Management and Efficiency are Critical: The company's focus on operating cost containment and leveraging technology to improve efficiency is essential for mitigating external pressures and returning to its long-term growth targets.
Focus of management’s prepared remarks
- Revised 2025 Outlook: Management revised the adjusted earnings per share outlook to $26-$26.50 due to increased care activity in UnitedHealthcare's Medicare Advantage business and unanticipated changes in Optum Medicare membership.
- Care Activity Increase: Care activity in UnitedHealthcare's Medicare Advantage business increased at twice the rate expected, primarily in physician and outpatient services.
- Optum Medicare Membership Changes: Unanticipated changes in Optum Medicare membership impacted 2025 revenue due to a lack of engagement from new patients covered by plans exiting markets and the impact of CMS risk model changes.
- Corrective Actions: Management outlined specific actions to address the performance challenges, including engaging complex patients, consistent member engagement, health status assessments, and investments in physician clinical workflow.
- Growth and Innovation: Despite the performance challenges, UnitedHealthcare's Medicare Advantage business is on pace to serve an additional 800,000 people, and Optum Health is on track to add 650,000 net new patients to value-based care arrangements.
- Optum Rx Performance: Optum Rx is experiencing strong growth, driven by new wins and high retention of long-term customers, underscoring the role of PBMs in reducing drug prices.
- Digital Engagement: New tools have sparked a more than 40% increase in digital engagement among senior members, leading to higher and earlier wellness visits.
- HouseCalls Program: The HouseCalls program in Medicare Advantage provides in-home clinical visits, helping to close care gaps and reduce hospital and emergency department visits.
- Initiatives for Simplicity and Affordability: Optum Rx will remove prior authorizations on 80 drugs, and payment models to pharmacies are being aligned more closely to their cost for drugs.
- Commitment to Transparency and Affordability: Management reiterated its commitment to transparency and affordability, highlighting the high cost of healthcare in the U.S. compared to other countries.
Focus of the analyst Q&A
- Medicare Advantage Cost Trends:
- What was the precise trend estimate assumed at the beginning of the year?
- What trend is now expected?
- How much did the first quarter MLR miss the company's own estimate?
- How different are the back three quarters expected to be versus the first quarter?
- Relationship Between Primary Care Visits and Optum Health Pressure:
- Why is higher follow-through expected if primary care is controlled?
- Why can costs be controlled better in a value-based care environment?
- What is the rationale for allocating more capital to value-based care?
- Drivers of Elevated Care on the MA Side:
- Is most of the elevated care being seen on the group side?
- Is this due to benefit and premium changes rather than an underlying uptick in utilization?
- Is the impact of competitive exits only on the Optum side?
- Is Part D performing as expected?
- Path to Long-Term Growth Rate:
- What are the key elements to get back to the long-term growth rate?
- MA Margins and Timeline for Recovery:
- Where are MA margins now expected to shake out inside the 2025 guidance?
- What is a reasonable timeline for recovering target margins?
- Is there any change to the long-term margin target in this business post V28?
- How confident is the company that it can improve margins in 2026 if trends stay at this level?
- PBM Reform and Medicaid Funding Cuts:
- What is the latest thinking in terms of PBM reform?
- What sort of permutations could be anticipated for Medicaid funding cuts?
- What is the company's ability to navigate these changes?
- Risks and Implications of Tariffs:
- What are the risks and implications of tariffs, particularly around pharmaceutical tariffs?
- Medicaid State Renewals:
- What is the update on state renewals through April?
- Is the company still on track to close the rate acuity gap by the end of the year?
- First Quarter MLR Impacts:
- What were the impacts driven by premium increases and deductible increases?
- Were there impacts as a result of changes in prior authorization?
- Was there increased follow-through from house calls and primary care actions tied to risk adjustment activity?
- Were there any one-time gains in the first quarter that supported the medical loss ratio?
- Impact of IRA on Pharma Manufacturers:
- Are the penalties under the IRA for pharma manufacturers who raise prices above inflation enough to protect the company from tariff pass-through on Medicare?
- Does this apply to exchanges as well?
- Will states give flexibility to submit two versions of bids with and without tariffs?
- Growth in C-SNP Plans:
- What does C-SNP enrollment mean from an economic perspective for UHC in 2025 and over the long term?
Summary
-
Financial Performance
UnitedHealth Group revised its adjusted earnings per share outlook for 2025 to $26-$26.50, a significant downward revision that management termed "unacceptable." Approximately 50% of the expected earnings are anticipated in the first half of the year. Consolidated revenue outlook remains affirmed at $450 billion to $455 billion. The full year medical care ratio is now expected to be 87.5%, plus or minus 50 basis points. Optum Health's revenue outlook is $106 billion to $107 billion, with operating earnings of $6.2 billion to $6.4 billion. UnitedHealthcare's operating earnings outlook is updated to $16 billion to $16.5 billion.
-
Revenue Drivers
Revenue changes are driven by better-than-expected performance at UnitedHealthcare and Optum Rx, offsetting a reduced outlook at Optum Health. Optum Rx revenues grew 14%, exceeding $35 billion for the quarter, driven by customer retention and new customer wins, contributing to script growth of 3%. UnitedHealthcare's Medicare Advantage business is on pace to serve an additional 800,000 people this year. Optum Health is on track to add 650,000 net new patients to value-based care arrangements. Commercial self-funded membership increased by approximately 700,000 in the first quarter.
-
Profit Margins and Cost Management
The medical care ratio is expected to be 87.5% plus or minus 50 basis points, reflecting higher utilization across senior populations and the patient mix and revenue profile of Optum Health. Management is focused on operating cost containment to mitigate external pressures. Technology advances are expected to drive further operating efficiency. Pressure was largely contained within the senior business at UnitedHealthcare, where a sharp increase in care activities was observed.
-
Guidance and Outlook
The company reaffirmed its consolidated revenue outlook of $450 billion to $455 billion. Adjusted earnings per share outlook for 2025 was revised to $26 to $26.50. UnitedHealthcare expects to serve up to 800,000 more people in Medicare Advantage this year. Optum Health continues to expect to add 650,000 new value-based care patients this year. The company aims to return to its long-term earnings per share growth target of 13% to 16%.
-
Strategic Initiatives
Key initiatives include engaging complex patients in clinical and value-based programs, consistent member engagement, health status assessments for new patients, and investments in physician clinical workflow. Optum Rx will remove prior authorizations on 80 drugs. Optum Rx has aligned payment models to pharmacies more closely to their cost for drugs. AI is being used to direct consumer calls to the right advocate.
-
Management Commentary
Management expressed dissatisfaction with the current performance but emphasized the company's growth and foundation for improvement. They highlighted the importance of Medicare Advantage and value-based care. They also emphasized the need for transparency and affordability in healthcare. The CEO stated the company is committed to improving performance in the rest of 2025 and into 2026 and returning to its long-term earnings per share growth target.
-
Industry and Market Conditions
The company noted that healthcare costs more in the U.S. than it should, citing disparities in drug prices and the cost of common procedures. They also mentioned the impact of Medicare funding cuts and the recently released 2026 rate notice, which begins to reflect accelerating care cost trends. The company is also closely monitoring potential pharmaceutical tariffs.
Comparative analysis
Add to research
Benchmarks (as of 2025-05-13)
Health Care Select Sector SPDR Fund (XLV)
- Performance Comparison:
- UnitedHealth Group, Inc. (UNH) has significantly underperformed the Health Care Select Sector SPDR Fund (XLV) across all time periods analyzed. For instance, the Year-To-Date (YTD) return for UNH is -38.02%, while XLV has a return of -3.8%, indicating a substantial underperformance of 34.22%. This trend is consistent across 1 week, 1 month, 3 months, 6 months, 1 year, 2 years and 3 years.
- Risk and Return Analysis:
- The annualized returns for UNH are consistently lower than those of XLV. For example, the 1-year annualized return for UNH is -38.87%, compared to -8.35% for XLV. This indicates that UNH has provided lower returns compared to the benchmark.
- UNH generally exhibited higher annualized volatility compared to XLV, especially during periods of market uncertainty. For example, in Q4 2024, UNH's volatility reached 42.34%, while XLV's was 13.6%.
- UNH experienced significantly larger drawdowns than XLV. The maximum drawdown for UNH was -49.79% on 2025-05-13, while the maximum drawdown for XLV was -15.11% on the same date. This indicates a higher risk profile for UNH.
- Risk-Adjusted Performance:
- The Sharpe ratios for UNH were generally lower than those of XLV throughout the analyzed period, indicating that XLV offered better risk-adjusted returns compared to UNH. In Q2 2025, both UNH and XLV had negative Sharpe ratios, with UNH at -0.94 and XLV at -0.37, indicating poor risk-adjusted returns, but UNH performed significantly worse.
- The beta values for both UNH and XLV were consistently below 1, indicating that both investments were less volatile than the overall market. In the most recent period, Q2 2025, UNH's beta was 0.17, while XLV's beta was 0.46, indicating that UNH has become even less sensitive to market movements compared to XLV.
- Overall Assessment:
- Based on the analysis, UnitedHealth Group, Inc. (UNH) has underperformed the Health Care Select Sector SPDR Fund (XLV) across all key metrics. UNH exhibits lower returns, higher volatility, larger drawdowns, and lower Sharpe ratios compared to XLV. While UNH's beta is lower, indicating less sensitivity to market movements, its overall risk-adjusted performance has been poor. The recent trends suggest that UNH's challenges persist, with significant underperformance and higher volatility compared to the broader healthcare sector.
Peers Price History(as of 2025-05-13)
-
Performance Comparison:
- UnitedHealth Group (UNH) has generally underperformed Humana (HUM) and Elevance Health (ELV) across most of the measured periods. For example, year-to-date, UNH's return is -38.02%, significantly lower than HUM's -9.11% and ELV's 3.05%. However, UNH has overperformed HUM over the 2-year and 3-year periods. For the 2-year period, UNH returned -34.02% compared to HUM's -55.3%, and for the 3-year period, UNH returned -33.45% compared to HUM's -46.68%.
-
Risk and Return Analysis:
- The annualized returns show that UNH has underperformed HUM and ELV over the 1-year period, with a return of -38.87% compared to HUM's -33.27% and ELV's -29.48%. Over the 2-year and 3-year periods, UNH has provided higher returns than HUM but lower returns than ELV.
- The annualized volatility of UNH has fluctuated throughout the period, with moderate levels in most quarters. However, in recent quarters, such as Q4 2024 and Q1 2025, UNH's volatility has increased. HUM has generally exhibited higher volatility compared to UNH and ELV, especially in recent periods.
- The maximum drawdown for UNH was -49.79% on 2025-05-13, which is less than HUM's maximum drawdown of -58.37% on the same date but more than ELV's maximum drawdown of -34.48% on 2025-01-02. This indicates that UNH has experienced significant declines from previous peaks, but not as severe as HUM.
-
Risk-Adjusted Performance:
- The Sharpe Ratio of UNH has varied throughout the period, with periods of positive and negative values. In general, UNH has had lower Sharpe Ratios compared to HUM and ELV, indicating lower risk-adjusted returns. In Q2 2025, all three companies had negative Sharpe ratios, with UNH at -0.94, HUM at -0.69, and ELV at -1.04.
- The Beta value of UNH has generally been below 1, indicating that UNH is less sensitive to market movements compared to the overall market. The Beta values for HUM have also been below 1, while ELV has had slightly higher Beta values compared to UNH and HUM.
-
Overall Assessment:
- UnitedHealth Group (UNH) has underperformed its peer companies, Humana (HUM) and Elevance Health (ELV), in terms of recent stock performance and annualized returns. While UNH has shown better performance than HUM over longer periods (2 and 3 years), its recent performance has been weaker. UNH's volatility has been moderate, but its maximum drawdown and Sharpe Ratio indicate a higher risk profile compared to ELV. The Beta value of UNH suggests that it is less sensitive to market movements compared to the overall market.
- A significant trend is the recent increase in volatility for all three companies, particularly in Q4 2024 and Q1 2025. This could be due to market uncertainty or company-specific factors. Additionally, HUM's higher volatility and larger drawdowns suggest a riskier investment profile compared to UNH and ELV.
Peers Fundamentals(as of 2025-03-31)
-
Market Position and Size:
- UnitedHealth Group (UNH) stands out with a significantly larger market capitalization of $359,092.47 million compared to Humana (HUM) at $30,386.88 million and Elevance Health (ELV) at $93,532.57 million.
- This substantial market cap is supported by higher revenue ($410,057.0 million), net income ($22,106.0 million), and operating cash flow ($28,516.0 million) compared to its peers.
- UNH's dominance in size reflects its leading position in the managed healthcare industry.
-
Profitability and Efficiency:
- UNH's net profit margin of 5.39% is notably higher than HUM's 1.42%, ELV's 3.23%, and the industry average of -0.97%, indicating efficient operations and strong cost management.
- The Return on Average Assets for UNH is 7.44%, which is also higher than HUM (3.39%), ELV (5.11%), and the industry average (-1.67%), demonstrating superior efficiency in generating returns from its assets.
- However, UNH's Cash Conversion Ratio of 1.15 is lower than HUM (3.76) and ELV (2.15), suggesting it is less efficient at converting revenue into cash.
-
Financial Health and Stability:
- UNH's current ratio of 0.85 is lower than HUM (1.91), ELV (1.43), and the industry average (1.28), indicating potential liquidity concerns.
- Despite this, UNH's cash flow to total debt ratio of 31.64 is higher than HUM (23.94) and ELV (24.54) and significantly exceeds the industry average (-7.1), suggesting a strong ability to service its debt.
- Overall, UNH's strong cash flow generation provides some offset to its lower liquidity position.
-
Valuation and Market Perception:
- UNH's Enterprise Value to Sales ratio of 1.38 is higher than HUM (0.38), ELV (0.7), and the industry average (0.79), suggesting a premium valuation relative to sales.
- Its Price to Earnings ratio of 16.49 is lower than HUM (17.8) and the industry average (21.86), but slightly higher than ELV (16.15), indicating it may be relatively fairly valued compared to its earnings.
- The Price to Book Ratio for UNH is 3.9, which is less than the industry average of 4.13, but greater than HUM (1.71) and ELV (2.2).
-
Cash Flow and Capital Management:
- UNH's Net Operating Cash Flow ($28,516.0 million) and Free Cash Flow ($24,862.0 million) are significantly higher than HUM and ELV, demonstrating strong cash flow generation capabilities.
- This robust cash flow supports its market position and growth initiatives.
-
Growth and Future Prospect:
- UNH's net income growth shows significant year-to-year fluctuation, with a standard deviation of 25.89%.
- UNH shows superior growth in net income, free cash flow, and free cash flow margin compared to the peer group average.
- The most recent year-over-year growth rates for net income, free cash flow, and free cash flow margin are significantly higher than their respective 5-year CAGRs, indicating an acceleration in growth.
-
Potential for Investment:
- UNH presents an attractive investment opportunity due to its strong market position, superior profitability, robust cash flow generation, and efficient asset utilization.
- While its liquidity position and valuation metrics warrant consideration, its overall financial performance and growth potential make it a compelling investment choice within the managed healthcare industry.
-
Key Risks and Considerations:
- UNH's lower current ratio compared to peers and the industry average indicates potential liquidity risks.
- The high volatility in UNH's growth rates and the recent acceleration in net income, free cash flow, and free cash flow margin growth warrant further investigation to assess their sustainability.
-
Overall Assessment:
- UNH demonstrates strong financial health, characterized by high profitability, robust cash flow generation, and efficient asset utilization.
- While its liquidity position warrants monitoring, its overall financial performance positions it favorably within its peer group and the broader industry.
Comparison metrics
Add to research